CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0847 (clinicaltrials.gov NCT No: NCT01102088)
Title:Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients with Esophageal Cancer
Principal Investigator:James Welsh
Treatment Agent:5-Fluorouracil; Docetaxel; Radiation
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of radiation that can be given in combination with chemotherapy in patients
with esophageal cancer that cannot be removed by surgery.

Hide details for General InformationGeneral Information

Disease Group:Esophagus
Phase of Study:Phase I/Phase II
Treatment Agents:5-Fluorouracil
Docetaxel
Radiation
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:n/a
Supported By:N/A
Return Visit:Patients will be assessed weekly during radiation therapy and 2 weeks after
radiation therapy and 6-8 weeks after completion of chemoradiation.
Home Care:n/a


Hide details for Study Contact InformationStudy Contact Information

Physician Name:James Welsh
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults